Pemetrexed Accord 1000 mg powder for concentrate for solution for infusion.

DRUG2 trials

Sponsors

Summit Therapeutics Inc., Universitair Ziekenhuis Gent

Conditions

Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatmentmetastatic non-small-cell lung cancer

Phase 1

A phase 1b study of an autologous dendritic cell immunotherapy in combination with anti-programmed death-1 treatment in patients with metastatic non-small-cell lung cancer (DARE-LUNG)

Not yet recruitingCTIS2025-521577-13-00

Universitair Ziekenhuis Gentmetastatic non-small-cell lung cancer

Target: 64Updated: 2025-09-11

Phase 3

A Randomized, Double-blind, Multi-center, Phase III Study of AK112 or Placebo Combined With Pemetrexed and Carboplatin in Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment (HARMONi)

Active, not recruitingCTIS2023-504434-22-00

Summit Therapeutics Inc.Patients With EGFR-mutant Locally Advanced or Metastatic Non-squamous NSCLC Who Have Failed to EGFR-TKI Treatment

Start: 2023-10-03Target: 45Updated: 2025-12-16